Lonza Forms Alliance and Acquires Stake in U.S. Drug Discovery Tech Firm

Lonza says it has signed an agreement with drug discovery technology company Odyssey Thera (San Ramon, CA) to make Odyssey Thera’s proprietary protein-fragment complementation assay (PCA) technology, and Odyssey Thera has granted to Lonza an option to certain exclusive global technology licenses. Lonza has made an equity investment in Odyssey Thera, and has become a minority shareholder in the company. Odyssey Thera, under the terms of the agreement, is eligible to receive technology development funding, milestones and royalties on Lonza product and service...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers